Granahan Investment Management LLC Trims Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Granahan Investment Management LLC cut its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 12.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 567,689 shares of the company's stock after selling 77,281 shares during the period. Granahan Investment Management LLC owned 1.07% of Stoke Therapeutics worth $6,262,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the company. Bank of New York Mellon Corp lifted its stake in shares of Stoke Therapeutics by 1.4% in the 4th quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company's stock valued at $1,028,000 after purchasing an additional 1,330 shares during the period. Gilder Gagnon Howe & Co. LLC lifted its position in Stoke Therapeutics by 2.0% during the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 92,546 shares of the company's stock valued at $1,021,000 after buying an additional 1,791 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Stoke Therapeutics by 6.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,455 shares of the company's stock valued at $414,000 after buying an additional 2,215 shares in the last quarter. Rhumbline Advisers grew its position in shares of Stoke Therapeutics by 6.0% in the 4th quarter. Rhumbline Advisers now owns 49,374 shares of the company's stock worth $545,000 after buying an additional 2,787 shares during the period. Finally, JPMorgan Chase & Co. increased its stake in shares of Stoke Therapeutics by 29.2% in the 4th quarter. JPMorgan Chase & Co. now owns 19,964 shares of the company's stock worth $220,000 after acquiring an additional 4,512 shares in the last quarter.

Insider Transactions at Stoke Therapeutics

In related news, insider Barry Ticho sold 3,884 shares of the company's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $33,674.28. Following the completion of the sale, the insider now owns 63,962 shares in the company, valued at approximately $554,550.54. This represents a 5.72 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of the firm's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the transaction, the director now directly owns 148,253 shares in the company, valued at $1,285,353.51. The trade was a 6.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 16,532 shares of company stock worth $143,332 over the last three months. 11.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

STOK has been the topic of several research reports. HC Wainwright reissued a "buy" rating and set a $47.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Needham & Company LLC restated a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, April 9th. Finally, Chardan Capital reaffirmed a "buy" rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $25.60.

Stoke Therapeutics Stock Up 2.2 %

NASDAQ:STOK opened at $9.25 on Friday. Stoke Therapeutics, Inc. has a 52 week low of $5.35 and a 52 week high of $17.58. The stock has a market cap of $505.02 million, a price-to-earnings ratio of -4.40 and a beta of 1.20. The company's 50 day moving average price is $8.03 and its 200-day moving average price is $10.07.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The company had revenue of $22.61 million for the quarter, compared to analysts' expectations of $4.20 million. As a group, sell-side analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.